期刊文献+

肺炎支原体合并Epstein-Barr病毒感染患儿的临床特征及免疫状况分析 被引量:9

Clinical characteristics and immune status of Epstein-Barr virus infections in children with Mycoplasma pneumoniae
原文传递
导出
摘要 目的探讨肺炎支原体合并Epstein-Barr病毒感染患儿的临床特征及免疫状况。方法选择2015年1月-2016年12月医院肺炎支原体合并Epstein-Barr病毒感染患儿80例作为实验组,另选取肺炎支原体未合并Epstein-Barr病毒感染患儿80例作为对照组,收集两组患儿的临床表现、实验室检查结果、影像学检查结果、免疫指标等资料。结果实验组患儿重症肺炎发生率为31.25%高于对照组6.25%(P<0.05),实验组发热时间和住院时间分别为(13.24±3.53)d、(13.98±4.21)d显著高于对照组(8.24±3.41)d、(9.78±4.04)d(P<0.05),两组肝肿大和淋巴结肿大发生率比较差异无统计学意义;实验组白细胞升高33.75%、AST升高36.25%、CK-MB升高42.50%均高于对照组的12.50%、11.25%、13.75%(P<0.05),两组血沉升高比例、CRP升高比例、降钙素原升高比例比较差异无统计学意义;实验组肺实变和胸腔积液的发生率分别为21.25%、30.00%高于对照组7.50%、10.00%(P<0.05),两组肺炎类型比较差异无统计学意义;实验组CD_4^+细胞(24.31±12.14)%、CD_8^+细胞(13.76±7.98)%、CD_4^+细胞/CD_8^+细胞(1.77±0.76)、B细胞(8.96±1.87)%、NK细胞(4.24±0.78%)均低于对照组(54.64±13.64)%、(20.02±8.68)%、(2.73±1.17)、(14.78±2.13)%、(11.32±1.53)%(P<0.05)。结论肺炎支原体合并Epstein-Barr病毒感染患儿病情更严重,肺炎支原体合并Epstein-Barr病毒感染对机体的损伤可能由免疫反应造成。 OBJECTIVE To investigate the clinical characteristics and immune status of Epstein-Barr virus infections in children with Mycoplasma pneumoniae.METHODS A total of 80 patients of M.pneumoniaeinfections with Epstein-Barr virus infections from Jan.2015 to Dec.2016 were selected as experimental group,and 80 patients of M.pneumoniaeinfection without Epstein-Barr virus infection were selected as control group.The clinical manifestations,laboratory findings,imaging results,immunological parameters and other data of the two groups of children were collected.RESULTS The incidence of severe pneumonia in experimental group was 31.25% ,which was higher than 6.25% in control group(P〈0.05).The time of fever and hospitalization in experimental group were(13.24±3.53)d and(13.98±4.21)d,which were significantly higher than(8.24±3.41)d and(9.78±4.04)d in control group(P〈0.05).There was no significant difference in the incidence of hepatomegaly and lymphadenopathy between the two groups.The elevated rates of leukocyte,AST and CK-MB in experimental group were 33.75% ,36.25% and 42.50% ,which were higher than 12.50% ,11.25% and 13.75% in control group(P〈0.05).There was no significant difference in the elevated rates of ESR,CRP and procalcitonin between two groups.The incidences of pulmonary consolidation and pleural effusion in experimental group were 21.3% and30.0% ,which were higher than 7.50% and 10.00% in control group(P〈0.05).There was no significant difference in the pneumonia type between the two groups.The CD4^+cells,CD8^+cells,CD4^+cells/CD8^+cells,B cells and NK cells in experimental group were(24.31±12.14)% ,(13.76±7.98)% ,(1.77±0.76),(8.96±1.87)% and(4.24±0.78)% ,which were lower than(54.64±13.64)% ,(20.02±8.68)% ,(2.73±1.17),(14.78±2.13)% and(11.32±1.53% )in control group(P〈0.05).CONCLUSION The condition of M.pneumoniae with Epstein-Barr virus infection children is more serious.The injury of M.pneumoniae with Epstein-Barr virus infection on the body may be caused by immune response.
出处 《中华医院感染学杂志》 CAS CSCD 北大核心 2017年第18期4220-4223,共4页 Chinese Journal of Nosocomiology
基金 浙江省医药卫生一般研究计划基金资助项目(2014KYB146)
关键词 儿童 肺炎支原体 EPSTEIN-BARR病毒 免疫 Children Mycoplasma pneumoniae Epstein-Barr virus Immunization
  • 相关文献

参考文献4

二级参考文献59

  • 1胡亚美,江载芳,主编.诸福棠实用儿科学[M].7版.北京:人民卫生出版社,2001:477-478.
  • 2Eun BW, Kim NH, Choi EH, et al. Mycoplasmapneu- moniae in Korean children: the epidemiology of pneumo- nia over an 18-year period [J]. J Infect, 2008, 56(5): 326- 331.
  • 3Williams SE, Brown TI, RoghanianA, etal. SLPI and elafin: one glove, many fingers [J]. Clin Sci (Lond), 2006, 110(1): 21-35.
  • 4Nukiwa T, Suzuki T, Fukuhara T, et al. Secretory leukocyte peptidase inhibitor and lung cancer [J]. Cancer Sci, 2008, 99(5): 849-855.
  • 5Sallenave JM. The role of secretory leukocyte proteinase inhibitor and elatin (elastase-specific inhibitor/skin-derived antileukoprotease) as alarm antiproteinases in inflammatory lung disease [J]. Respir Res, 2000, 1(2): 87-92.
  • 6Sallenave JM. Secretory leukocyte protease inhibitor and elafin/trappin-2:versatile mucosal antimicrobials and regulators of immunity [J]. Am J Respir CeU Mol Biol, 2010, 42(6): 635-643.
  • 7Lentsch AB, Jordan JA, Czermak BJ, et al. Inhibition of NF-kappaB activation and augmentation of IkappaBbeta by secretory leukocyte protease inhibitor during lung inflammation [J]. Am J Pathol, 1999, 154(1): 239-247.
  • 8Weldon S, McNally P, McElvaney NG, et al. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation [J]. J Immunol, 2009, 183(12): 8148-8156.
  • 9Wex T, Treiber G, Venerito M, et al. Helicobacter pylori-induced downregulation of the secretory leukocyte protease inhibitor (SLPI) in gastric epithelial cell lines and its functional relevance for H. pylori-mediated diseases [J]. BiolChem, 2006, 387(7): 893-901.
  • 10Huppert JS, Huang B, Chen C, et al. Clinical evidence for the role of Trichomonas vaginalis in regulation of secretory leukocyte protease inhibitor in the female genital tract [J]. J Infect Dis, 2013, 207(9): 1462-1470.

共引文献71

同被引文献86

引证文献9

二级引证文献94

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部